Phase 2 N=275 OK432 (Picibanil) in the Treatment of Lymphatic Malformations
Lymphatic Malformations
Primary: Number of Participants With Clinical Success at 1 to 6 Months Post-Therapy as Assessed by Imaging — 57 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=7 A Study to Evaluate Sildenafil for the Treatment of Lymphatic Malformations
Lymphangioma
Primary: Change in Volume of Lymphatic Malformation — 3.7; -4.3; -1.0; -31.7 percentage of volume change
Phase 2 N=19 Sildenafil for the Treatment of Lymphatic Malformations
Lymphatic Malformations · Lymphatic Diseases
Primary: Change in Lesion Volume of the Test Medication as Evaluated by MRI Examination. — 5.89; -8.54; -0.642 percentage of volume
Phase 2 N=12 Study Evaluating the Safety and Efficacy of PTX-022 (QTORIN Sirolimus) in the Treatment of Microcystic Lymphatic Malformations
Microcystic Lymphatic Malformation
Primary: Incidence of Treatment-Emergent Adverse Events — 9; 2; 6; 2 participants
N/A N=18 Influence of Flat-knitted Compression Stockings Class I and II on Venous Malformations
Vascular Malformations · Vascular Malformation Peripheral · Venous Malformation
Primary: Volume Difference of Malformation to Baseline (no Compression) While Wearing Compression Stockings Class I and II Determined by MRI — 16.38; 23.7 ml
Phase 2 N=4 Treatment With Octreotide in Patients With Lymphangioleiomyomatosis
Lymphangioleiomyomatosis · Lymphangiomyomas · Pleural Effusions
Primary: Number of Participants With a Reduction in Total Tumor Volume of at Least 20%. — 0 Participants
N/A N=80 A Study for Lymphocele and Lymphorrhea Control Following Inguinal and Axillary Radical Lymph Node Dissection
Lymph Node Dissection · Lymphoedema · Lymphocoele
Primary: Postoperative Draining Time — 31; 32 days
N/A N=13 Upper Extremity Lymphatic Mapping for Breast Cancer Patients
Breast Cancer · Axillary Lymph Node Dissection
Primary: Number and Prevalence of Metastases of Blue Nodes in the ALND Specimen (Nodes Draining the Breast). — 0 participants
N/A N=18 Imaging Biomarkers of Lymphatic Dysfunction
Secondary Lymphedema
Primary: Assessing a Change in Bioimpedance Spectroscopy (BIS) — 1.3; 1.8 Change of score on a scale
N/A N=357 Hemangioma Associated With High Rates of Morbidity
Hemangioma
Primary: MRI/MRA of Head/Neck/Chest. — 357 participants
Phase 3 N=89 Efficacy and Safety of Sirolimus in LAM
Lymphangioleiomyomatosis
Primary: Changes in Forced Expiratory Volume in One-second (FEV1) Slope in Milliliters Per Month — 1; -12 milliliters per month — p=<0.001
N/A N=194 Effectiveness of Fluoroscopy-guided MLD for Treatment of BCRL
Breast Neoplasm · Lymphedema
Primary: Lymphoedema Volume at the Level of the Arm/ Hand — 1.228; 1.249; 1.218; 1.175 Inter-limb ratio
Phase 2 N=82 Acupuncture for Chronic Lymphedema
Breast Cancer With Chronic Lymphedema
Primary: Lymphedema as Measured at Baseline and at 6 Weeks — 4.74; 4.82; 4.29; 4.76 cm
Phase 2 N=10 A Study of Vascular Endothelial Growth Factor (VEGF) Inhibition in Patients With Unilateral Upper Extremity Lymphedema Following Treatment for Cancer
Lymphedema
Primary: Change in Volume Ipsilateral Lymphedema in Arm — -161.0; -372.8 mL — p=0.0658
Phase 4 N=50 Lymphedema Study for Arm or Leg Lymphedema
Lymphedema
Primary: Part 1: Count of Participants Able to Complete Ketoprofen Treatment — 50 Participants
N/A N=34 Vasculera in Participants With Lipedema
Lipedema
Primary: Change in Weight From Baseline — 0.340 kilograms — p=0.473
Phase 4 N=50 Low Level Laser Treatment and Breast Cancer Related Lymphedema
Lymphedema
Primary: LDex Change- — 28.0; 17.8; 22.2 LDex
N/A N=21 LLLT Combined With CDT in Breast Cancer-Related Lymphedema
Breast Cancer · Lymphedema
Primary: Arm Volume — 1.48; 1.58 cm^3
Phase 2 N=11 Response to Intermittent Pneumatic Compression Therapy in Head and Neck Cancer-Related Lymphedema
Head and Neck Neoplasms · Head and Neck Lymphedema · Head and Neck Cancer
Primary: Lymph Movement Measured by ICG Lymphography. — 5; 5; 0; 0 Participants
Phase 2 N=24 A Study of Lymphoseek® as a Lymphoid Tissue Targeting Agent in Pediatric Patients With Melanoma, Rhabdomyosarcoma, or Other Solid Tumors Who Are Undergoing Lymph Node Mapping
Rhabdomyosarcoma · Melanoma
Primary: Average Number of Lymph Nodes Identified Intraoperatively Per Subject — 3.30 nodes per subject
N/A N=1 Prospective Evaluation of a Surgical Solution for Breast Cancer-Associated Lymphedema
Lymphedema · Edema
Primary: Change in Limb Volume — -15; -202 mL
Phase 3 N=163 Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes
Breast Cancer · Melanoma
Primary: Concordance of Blue Dye and Lymphoseek — 1.0000 Proportion of Lymph Nodes
N/A N=25 Low-Level Laser in Head and Neck Chronic Lymphedema
Head and Neck Cancer · Lymphedema · Fibrosis
Primary: Total Severity of External Lymphedema and Fibrosis (LEF) — 5.42; 4.08; 3.22; 4.62 score on a scale
N/A N=89 Infrared Lymphangiography as a Method of Sentinel Node Identification
Melanoma · Sentinel Node
Primary: Equivalence of ICG and Real Time Lymphangiography to technetium99 and Blue Dye in Localizing Sentinel Nodes — 1.87 number of sentinel nodes per patient
N/A N=12 Low-Level Laser in Treatment of Head and Neck Lymphedema: A Pilot Study
Head and Neck Cancer · Lymphedema · Fibrosis
Primary: Number of Participants Consented and Enrolled in Study — 12 Participants
N/A N=32 Fibrin Glue in Inguinal Lymphadenectomy
Seroma
Primary: Number of Participants With Seroma Formation — 2; 8 participants — p=0.022
Phase 2 N=61 Safety and Efficacy Study of Sirolimus in Complicated Vascular Anomalies
Kaposiform Hemangioendotheliomas · Tufted Angioma · Capillary Venous Lymphatic Malformation
Primary: Overall Response by Radiologic Evaluation, Quality of Life Assessment, and Functional Impairment Score — 47; 7; 3 Participants
Phase 4 N=74 Post-Operative Drainage Following Lymph Node Dissection
Malignant Melanoma · Carcinoma, Squamous Cell
Primary: Post-operative Wound Drainage. — 892.5; 762.5; 565; 590 ml — p=0.704
N/A N=36 Intermittent Pneumatic Compression in Women With Lipo-lymphedema (Lipedema With Swelling)
Lipedema · Lipolymphedema
Primary: Change in Circumferential Measurements Over Time — -0.5; -1.0; -1.3; -2.0 cm
N/A N=72 Disability and Quality of Life in Patients With Lymphatic Filariasis in Rural Southern India
Lymphatic Filariasis
Primary: Dermatology Life Quality Index (DLQI) Domain Scores — 3; 0; 1; 0 units on a scale